Skip to main content
. Author manuscript; available in PMC: 2023 Jan 20.
Published in final edited form as: Cancer Res Commun. 2022 Jun 6;2(6):402–416. doi: 10.1158/2767-9764.CRC-22-0124

Figure 4. Chronic SMOi treatment reduces specific HAT and HDAC protein levels in SI-CSC MBs in vitro and in vivo.

Figure 4.

Western blot analyses of histone acetyl transferases and histone deacetylases in vehicle vs. LDE225 -resistant fSmoM2M2;hGFAP-cre and Ptch;p53 SHH MBs. (A, D) fSmoM2M2;hGFAP-cre SI-CSC, (B, E) Ptch;p53 SI-CSC MBs and (C, F) Ptch;p53 SD-CSC MBs. G) Western blot analyses of LDE225-resistant Ptch;p53 SI-CSC tumorsphere cells treated with LDE225 for long-term (> 2 weeks) in vitro show the same HAT and HDAC expression changes. H) Acute (24 hours) treatment of Ptch;p53 SI-CSC tumorsphere cells show no significant changes in CBP, GCN5, or HAT1 protein levels in response to short-term LDE225 treatment.